CTN 0015: Preliminary findings from the Women and Trauma Study - PowerPoint PPT Presentation

About This Presentation
Title:

CTN 0015: Preliminary findings from the Women and Trauma Study

Description:

– PowerPoint PPT presentation

Number of Views:80
Avg rating:3.0/5.0
Slides: 48
Provided by: gmi9
Learn more at: https://ctnlibrary.org
Category:

less

Transcript and Presenter's Notes

Title: CTN 0015: Preliminary findings from the Women and Trauma Study


1
CTN 0015 Preliminary findings from the Women
and Trauma Study
  • Denise Hien, Ph.D.
  • Research Scientist, Social Intervention Group,
  • Columbia University School of Social Work
  • Executive Director, Womens Health Project
    Treatment and Research Center, Addiction
    Institute of New York, St. Lukes\Roosevelt
    Hospital Center
  • St. Petersburg, Florida
  • December 7, 2006
  • PLEASE DO NOT CITE CONTENTS OF PRESENTATION
    WITHOUT PERMISSION OF THE AUTHOR

2
  • The past isnt dead, it isnt even past.
  • -William Faulkner

3
Scope of the Problem
  • 1 in 2 women in the U.S. experience some type of
    traumatic event (Kessler, 1995)
  • Approximately 33 of females under age 18
    experience sexual abuse (Finkelhor, 1994 Wyatt,
    1999)
  • Prevalence rates of PTSD in community samples
    have ranged from 6 to 36 (Breslau, 1991
    Kilpatrick, 1987 Norris, 1992 Resnick, 1993)
  • Studies have documented PTSD rates among
    substance using populations to be between 14-60
    (Brady, 2001 Donovan, 2001 Najavits, 1997
    Triffleman, 2003)

4
Neurobiological Changes in Response to Traumatic
Stress
  • Limbic System -- Hippocampus and Amygdala (Affect
    and Memory, e.g, Ledoux, 2000 van der Kolk,
    1996)
  • Neurotransmitters and Peptides (Numbing and
    Depression, e.g., Pitman, 1991, Southwick, 1999)
  • Changes in Hormonal System (HPA axis) (Arousal,
    e.g., Yehuda, 2000)

5
Historical Context for the Study of Trauma
Addiction
Womens movement and grassroots advocacy for
battered women
Crack/ Cocaine epidemic
Fulliloves snowball sample
1970 1980 1990
PTSD studies with male veterans with/out
substance use
DSM-IIIR broadens criteria for PTSD
Millers work with criminal justice population
6
Historical Context for the Study of Trauma
Addiction
Kendler et al. co-twin study suggesting causal
link between abuse and SUD
Chilcoat and Breslau self-medication model
SAMSHA findings published
Hermans Trauma and Recovery published
1990 1995 2000 2006
RCTs of integrated PTSD and SUD tx
National awareness of PTSD and addiction
following 9/11/01
Violence declared public health epidemic
Manualized integrated trauma and SUD tx
7
Differences between Co-morbid PTSD vs. PTSD-only
behavioral treatments
  • Addition of components focused on coping and
    cognitive restructuring related to substance use
    (cravings and relapse triggers)
  • Concurrent Model Additional components may be
    integrated and delivered concurrently
  • Sequential Model Initial phase may focus on
  • substance abuse related symptoms in
    preparation for
  • working on trauma related symptoms later

8
PTSD/SUD Behavioral Treatments
  • ATRIUM Addictions and Trauma Recovery Integrated
    Model (Miller Guidry, 2001)
  • Seeking Safety (Najavits, 1998
    www.seekingsafety.org)
  • TARGET - Trauma Affect Regulation Guidelines for
    Education and Therapy (Ford www.ptsdfreedom.org)
  • Transcend (Donovan et al., 2001)
  • CTPCD - Concurrent Treatment of PTSD and Cocaine
    Dependence (Back et al., 2001)
  • SDPT Substance Dependence PTSD Therapy
    (Triffleman et. al, 1999)

9
NIDA Clinical Trials Network Women Trauma Sites
Washington Node Residence XII
New England Node LMG Programs
Ohio Valley Node Maryhaven
New York Node ARTC
Long Island Node Lead Node
South Carolina Node Charleston Center
Florida Node Gateway Community
Florida Node The Village
10
CTN Long Island Node Team
  • Denise Hien, Lead Investigator
  • Edward Nunes, Node PI
  • Gloria Miele, Training Director
  • Lisa Cohen, Protocol Manager
  • Aimee Campbell, Project Director
  • Jennifer Lima, Node Coordinator
  • Eva Petkova, Lead Statistician
  • Huiping Jiang, Statistician
  • David Liu, NIDA Liaison

11
Participating Nodes and CTPs
12
CTN Women Trauma A Unique Opportunity
  • Chance to conduct a practical clinical trial on
    SS while maintaining a rigorous control
  • Shorter treatment window and dose
  • Open-group, rolling admissions format paralleling
    real world
  • Community treatment providers as research
    clinicians
  • Treatment as usual while receiving research
    intervention

13
Study Aims
  • To assess the effectiveness of adding Seeking
    Safety (SS) and Womens Health Education (WHE)
    groups to ongoing substance abuse treatment.
  • To evaluate the transportability of a 12- session
    group version of SS in community drug/alcohol
    treatment settings.

14
Pre-Post Control Group Design
Pre-screening, Screening, Baseline,
Randomization, Individual Counselor Session
Pre-Treatment 1 - 4 Weeks
Treatment 6 Weeks
12 Twice Weekly Group Sessions
Post Treatment Follow-up 46 Weeks
1 Week
3 Month
6 Month
12 Month
15
Treatment Groups
  • Seeking Safety (SS)
  • Short term, manualized treatment
  • Cognitive Behavioral
  • Focused on addiction and trauma
  • Womens Health Education (WHE)
  • Short term, manualized treatment
  • Psychoeducational
  • Focused on womens health information and issues

16
Seeking Safety
  • Developed as a group treatment for PTSD/SUD women
  • Based on CBT models of SUDs, PTSD treatment,
    womens treatment and educational research
  • Educates patients about PTSD and SUDs and their
    interaction
  • Goals include abstinence and decreased PTSD
    symptoms
  • Focuses on enhancing coping skills, safety and
    self-care
  • Active, structured treatment - therapist
    teaches, supports and encourages
  • Case management

Najavits, 2002 www.seekingsafety.org
17
Womens Health Education
  • Empowerment
  • Information is empowering
  • Self-care
  • Substance abuse and trauma interfere with ability
    to
  • care for oneself
  • Exposure to traumatic stress can affect people on
    many
  • different levels of functioning including
  • emotional
  • behavioral
  • physical
  • There is significant overlap of PTSD and physical
    symptoms
  • In the national comorbidity survey, use of
    medical care services was highest in PTSD and
    panic disorder patients (Kessler, 1995)

18
Assessment Domains
  • Demographics
  • Substance Abuse/Dependence Diagnosis
  • CIDI Composite International Diagnostic
    Interview
  • Substance Use
  • SUI Substance Use Inventory (Primary)
  • Biological Urine/Saliva Screen (Primary)
  • ASI Addiction Severity Index
  • HIV Risk Behaviors RBS Risk Behavior Survey
  • Health and Family Network (ASI add-on questions)

19
Assessment Domains
  • PTSD Diagnosis and Symptoms
  • CAPS Clinician Administered PTSD Scale
    (Primary)
  • PSS-SR Post Traumatic Stress Symptoms Self
    Report
  • Trauma Exposure Lifetime Events Checklist
  • Psychiatric Symptoms BSI Brief Symptom
    Inventory
  • Service Utilization TSR Treatment Services
    Review (medication)

20
In-Treatment Measures(baseline, weekly through
treatment,1week post)
  • PTSD Symptoms (PSS-SR)
  • Biologically Confirmed Substance Abstinence and
    Proportion of Days Used
  • Substance Use Inventory (SUI)
  • Urine Drug Screen (UDS)
  • Saliva Alcohol Screen (ST)

21
Participant Eligibility Criteria
  • Inclusion
  • female, 18 - 65 years old
  • used an illicit substance within the past six
    months and have a current diagnosis of illicit
    drug/alcohol abuse or dependence
  • PTSD or Sub-threshold PTSD
  • enrolled at participating community treatment
    program
  • Exclusion
  • advanced stage medical disease (AIDS, TB)
  • impaired mental status (MMSE less than or equal
    to 21)
  • significant risk of suicidal/homicidal intent or
    behavior
  • history of schizophrenia-spectrum diagnosis
  • active psychosis (prior 2 months)
  • involved in PTSD-related litigation
  • refuses to be audio or videotaped

22
Enrollment
Initial Screen N1,963
Ineligible N751
Eligible for Baseline N1,212 (62)
No Full Screen N751
Completed Baseline N541 (45)
Ineligible N162
Eligible for Randomization N379 (70)
Not Randomized (multiple reasons) N26
Randomized N353 (93)
23
Sample Characteristics (N353)
24
PTSD Diagnosis and Severity at Baseline (N353)
25
Substance Use Disorders at Baseline (N353)
Note not exclusive categories
26
Lifetime Trauma Exposure (N353)
27
Data Analytic Approach for In-Treatment Outcomes
  • Mixed effect models were used to model the
    outcome measures of interest as a function of
    baseline levels, time, treatment, site and their
    interactions.
  • A non-randomized sample of naturalistically-occurr
    ing wait list controls was examined with
    baseline as the pre-test and assessment during
    1st week of treatment as the post-test.
  • Additional analyses on the impact of treatment
    attendance on outcomes were conducted.

28
PTSD In-Treatment Outcomes PSS-SR severity
modeled from pre-treatment to post-treatment
weekly by treatment group
29
PTSD In-Treatment Outcomes PSS-SR frequency
modeled from pre-treatment to post-treatment
weekly by treatment group
30
SUD In-Treatment Outcomes Abstinence rates
modeled from pre-treatment to post-treatment
weekly by treatment group
31
SUD In-Treatment Outcomes Days of use modeled
from pre-treatment to post-treatment weekly by
treatment group
32
Secondary Analyses Six Week Pre- Post Changes
for Non-Randomized Naturalistic Wait Group (N20)
Wait List
33
Secondary Analyses Treatment Attendance Rates
No significant differences between groups
34
Secondary Analyses Effects of treatment
attendance on post-treatment abstinence rates
35
Secondary Analyses Effects of treatment
attendance on post-treatment days of use
36
Comments
  • Though all participants met PTSD and SUD
    diagnoses as per study inclusion criteria,
    findings show that within this sample population
    there was substantial variability across sites in
    terms of types of trauma exposure, types of drugs
    used and specific drug use diagnoses.
  • Despite such differences in site characteristics,
    overall, both SS and WHE groups led by community
    substance abuse counselors can reduce PTSD
    symptoms at a statistically significant level.
  • Although SUD outcomes were not statistically
    significant by the end of six weeks of treatment,
    they were reduced from baseline and the number of
    sessions received did significantly predict
    lowered levels of SUD symptoms.
  • We speculate that the reductions observed in PTSD
    symptoms during treatment, particularly in the SS
    group, may be more pronounced over the follow up
    period and lead to greater reductions in SUD
    symptoms over time.

37
(No Transcript)
38
Project Directors/Protocol PIs
  • Frankie Kropp
  • Agatha Kulaga
  • Melissa Gordon
  • Chanda Brown
  • Silvia Mestre
  • Nadja Schreiber
  • Mary Hatch-Maillette
  • Chris Neuenfeldt
  • Cheri Hansen
  • Karen Esposito
  • Sharon Chambers

39
CTN-0015 Research Staff
  • Brianne OSullivan
  • Ileana Graf
  • Melissa Chu
  • Nishi Kanukollu
  • Treneane Salisbury
  • Rebecca Krebs
  • Ann Whetzel
  • Stella Resko
  • Carol Hutchinson
  • Chanda Brown
  • Janice Ayuda
  • Pamela Bernard
  • Jessica Ucha
  • Nicole Moodie
  • Allison Kristman-Valente
  • Lynette Wright
  • Melanie Spear
  • Lisa Johnson
  • Catherine Williams
  • Calonie Gray
  • Michele DiBono
  • Rachel Hayon
  • Barbara Bettini
  • Barbara Thomas
  • Lisa Markiewicz
  • Elizabeth Cowper
  • Rosaline King
  • Lara Reichert

40
CTN-0015 Clinicians
  • Lisa Cohen
  • Dawn Baird-Taylor
  • Lisa Litt
  • Martha Schmitz
  • Karen Tozzi
  • Darlene Franklin
  • Kathleen Estlund
  • Molly McHenry-Whalen
  • Erin Demirjian
  • Anslie Stark
  • Karen Bowes
  • Metris Batts
  • Felisha Lyons
  • Kathy McPherson
  • Victoria Johnson
  • Denese Lewis
  • Sharon Anderson-Goss
  • Merilee Perrine
  • Angela Waldrop
  • Leslie Lobel-Juba
  • Maria Mercedes Giol
  • Lourdes Barrios
  • Lisa Mandelman
  • Jeanette Suarez
  • Danielle Macri
  • Maria Hurtado
  • Tina Klem
  • Nancy Magnetti
  • Anne Marie Sales
  • Renee Sumpter
  • Michelle Melendez
  • Ida Landers
  • Regina Morrison
  • Clare Tyson
  • Mary Hodge-Moen
  • Sandra Free
  • Goldie Galloway
  • Karen Canida

41
CTN-0015 QA and Data Management
  • Jim Robinson
  • JP Noonan
  • Connie Klein
  • Karen Loncto
  • Chris Hutz
  • Lauren Fine
  • Michelle Cordner
  • Melissa Gordon
  • Maura Weber
  • Kristie Smith
  • Catherine Dillon
  • Donna Bargoil
  • Jurine Lewis
  • Girish Gurnani
  • Inna Logvinsky
  • Peggy Somoza
  • Sharon Pickrel
  • Katie Weaver
  • Molly Carney
  • Catherine Otto
  • Rebecca Defevers
  • Emily DeGarmo
  • Royce Sampson
  • Stephanie Gentilin
  • Clare Tyson
  • Anthony Floyd
  • Nathilee Francois

42
  • Appendices Summary Data Tables

43
Comparison of Existing Trauma / SUD- Focused
Treatment Research
44
Summary Statistics for Post-treatment PSS-SR
Severity Modeled by Baseline PTSD Severity,
Demographics, Treatment Group, Time, Site, and
their Interactions
45
Summary Statistics for Post-treatment PSS-SR
Frequency Modeled by Baseline PTSD Frequency,
Demographics, Treatment Group, Time, Site, and
their Interactions
46
Summary Statistics for Post-treatment Days of Use
Modeled by Baseline Days of Use, Demographics,
Treatment Group, Time, Site, and their
Interactions
47
Summary Statistics for Post-treatment Abstinence
Rates Modeled by Baseline Abstinence,
Demographics, Treatment Group, Time, Site, and
their Interactions
Write a Comment
User Comments (0)
About PowerShow.com